|
// The Frontier
Your body keeps the plans
Three labs are learning to read them back. Here is what they found.
|
|
| |
|
|
| |
// SuperSight
Each cell in your eye runs on a kind of code that tells it what to be.
With time, that code gets messy. Cells lose track of their jobs.
Life Biosciences, co-founded by Harvard’s David Sinclair, built a gene therapy to tidy it up. It uses three genes, known as OSK, to reset cells to a younger state.
In June, the first person got a dose. The trial covers two optic nerve conditions, one of them glaucoma.
It’s the first time this reset has been tried in a human.
PHASE: 1 · FIRST DOSE: June 2026 · GENES: 3
→ Source: Washington Times, June 2026
|
|
| |
|
|
|
| |
|
|
| |
// SuperHearing
Some kids are born deaf because of one faulty gene, called OTOF.
Their ears are built fine. The hair cells just can’t pass sound on to the brain.
A Harvard-led team slipped a good copy of the gene into the inner ear. Of 42 people, 90% heard better. After two and a half years, more than half had normal hearing.
“They can hear a whisper,” said Dr. Zheng-Yi Chen.
Meanwhile, the FDA cleared a similar gene therapy in April. It was the first of its kind.
PEOPLE: 42 · HEARD BETTER: 90% · TRACKED: 2.5 years
→ Source: Nature, via Harvard Med, 2026
|
|
| |
|
|
|
| |
|
|
| |
// SuperStrength
Strength can fade long before muscle size does. A team at the University of Missouri found out why.
The clue sits at the spot where nerve meets muscle. With age, a protein there called NaV1.4 runs low. So the muscle stops hearing the nerve’s call.
In lab animals, the team partly blocked a second protein, ClC-1. The muscle tuned back in… and strength came back with it.
A drug that works this way, from a Danish firm, is in human trials for a nerve disease.
TARGET: ClC-1 · MODEL: lab animals · JOURNAL: JCI
→ Source: Univ. of Missouri, Sept 2026
|
|
| |
|
|
|
|
|
So what does this mean for you?
Here’s the thing. None of these three is a pill you can buy off a shelf.
But they all point the same way. Your body holds on to the plans… and waits for the right cue.
For muscle, you can send that cue yourself with a heavy weight.
I pay over $20,000 a year for the same deep research tools hedge funds use. That lets me read the trials, not the headlines.
If a claim has no trial behind it, it doesn’t make it in here. Each stat above links to its source, so you can check my work.
And yes, I’m on my own heavy year. Three | |